BriaCell Therapeutics Corp. (BCT)
TSX 
Summary
BCT Chart
Top 3 Earnings Acceleration Buys for November
Groupon, BriaCell Therapeutics and InnovAge stand out with accelerating earnings momentum as November's market optimism approaches.
All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy
BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotechs on the Brink: 2 Stocks With Huge Potential
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and other medical products, but the process can be slow and, for those on the outside, opaque. Then, if all goes according to plan, these firms may see success in the form of promising data, successful trial results, or approval from a regulatory agency like the FDA.
BriaCell Therapeutics Corp. (BCT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has BriaCell Therapeutics Corp. ever had a stock split?
BriaCell Therapeutics Corp. Profile
| Biotechnology Industry | Healthcare Sector | William V. Williams FCPA, CEO | TSX Exchange | CA10778Y3023 ISIN |
| CA Country | 16 Employees | - Last Dividend | 26 Aug 2025 Last Split | - IPO Date |
Overview
BriaCell Therapeutics Corp. is a Phase 3 biotechnology company dedicated to revolutionizing cancer care through the development of novel cellular immunotherapies. Positioned at the forefront of oncological treatment, BriaCell is focused on advancing a pivotal Phase 3 clinical trial targeting advanced breast cancer. This trial involves the innovative Bria-IMT in combination with immune checkpoint inhibitors, aiming to significantly enhance patient outcomes. Demonstrating its commitment to addressing unmet medical needs in oncology, BriaCell also pioneers the development of personalized, off-the-shelf treatments for various cancers, including breast and prostate cancer. Based in West Vancouver, Canada, the company leverages strategic collaborations, notably with Incyte Corporation, to explore and potentially maximize the efficacy of its therapies, thereby positioning itself as a leader in the field of cancer immunotherapy.
Products and Services
- Bria-IMT in combination with immune checkpoint inhibitors
This innovative approach to cancer immunotherapy is at the heart of BriaCell's pivotal Phase 3 clinical trial for advanced breast cancer. Bria-IMT is designed to attack cancer cells by engaging the immune system, and when used in conjunction with immune checkpoint inhibitors, the combination therapy aims to enhance the immune system's response to tumors. This cutting-edge treatment strategy represents a promising advancement in the fight against breast cancer, offering hope for improved patient outcomes.
- Personalized Off-the-Shelf Treatments
BriaCell is at the forefront of developing tailored treatments for cancer, focusing on personalization without the wait. These off-the-shelf therapies target various types of cancer, including breast and prostate cancer, by leveraging the unique characteristics of each patient's tumor. By advancing these personalized treatments, BriaCell aims to provide more effective cancer care that is both faster and more accessible than traditional personalized therapies, making a significant impact on patient care in oncology.
Contact Information
